Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 149 No. 1112 (2019)

Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

  • Sarah Blach
  • Christian Schaetti
  • Philip Bruggmann
  • Francesco Negro
  • Homie Razavi
DOI
https://doi.org/10.4414/smw.2019.20026
Cite this as:
Swiss Med Wkly. 2019;149:w20026
Published
24.03.2019

Summary

BACKGROUND AND AIMS

A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years.

METHODS

A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the economic impact of each scenario. Additionally, we generated a net-zero cost scenario (Scenario 2), assuming the same treatment paradigm as Scenario 1 but at the treatment price that would break even by 2031.

RESULTS

In the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031. Cumulative direct costs are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031. In Scenario 1, annual direct costs first increased to 175 million CHF by 2018, before declining to 44 million CHF by 2031. Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031. For Scenario 2, the treatment price needed to achieve break-even by 2031 considering only direct costs would be 27,900 CHF per patient.

By 2031, Scenarios 1 and 2 would gain 58,300 QALYs. In both scenarios, the ICER drops below the cost-effectiveness threshold of 78,000 CHF in 2018. Over the 15-year span, the ICER was determined to be 2,200 CHF for Scenario 1.

CONCLUSIONS

Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared to the historical base case and could achieve break-even by 2031 at a price of 27,900 CHF.

References

  1. Zahnd C, Brezzi M, Bertisch B, Giudici F, Keiser O. Situation Analysis on hepatitis B and C in Switzerland [Online]. Federal Office of Public Health; 2017 [Available from: www.bag.admin.ch/situationsanalyse-hepatitis.
  2. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29–37. doi:.https://doi.org/10.1111/j.1360-0443.2009.02741.x
  3. Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One. 2015;10(6):e0125214. doi:.https://doi.org/10.1371/journal.pone.0125214
  4. Swiss Hepatitis Strategy 2014-2030. Time to Act Now! Process Paper - A Living Document. http://www.hepatitis-schweiz.ch/files/Dokumente/Process_Paper_2nd_version_final.pdf. 2015.
  5. World Bank. GDP per capita (current US$) Washington, D.C.2015 [Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
  6. Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, et al.; ESGHV (part of ESCMID). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 2018;150:9–14. doi:.https://doi.org/10.1016/j.antiviral.2017.12.001
  7. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al.; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76. doi:.https://doi.org/10.1016/S2468-1253(16)30181-9
  8. WHO. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 Towards Ending Viral Hepatitis. World Health Organization; 2016.
  9. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14. doi:.https://doi.org/10.7326/0003-4819-144-10-200605160-00004
  10. Federal Office of Public Health. Swiss mandatory notifications for hepatitis C per canton, FOPH/CD/EPI/RIC 29.08.16. 2016.
  11. Health IMS. IMS Health MIDAS Data 2013 [updated 1/1/2013. Available from: http://www.imshealth.com/.
  12. Vitali GC, Laurent A, Terraz S, Majno P, Buchs NC, Rubbia-Brandt L, et al. Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤3 cm) hepatocellular carcinoma: a case-control study. Surg Endosc. 2016;30(6):2301–7. doi:.https://doi.org/10.1007/s00464-015-4295-6
  13. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016;176(1):65–73. doi:.https://doi.org/10.1001/jamainternmed.2015.6011
  14. Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One. 2015;10(5):e0126984. doi:.https://doi.org/10.1371/journal.pone.0126984
  15. Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, et al. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly. 2015;145:w14221. doi:.https://doi.org/10.4414/smw.2015.14221
  16. Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(Suppl 1):S22–6. doi:.https://doi.org/10.1016/j.drugpo.2014.08.014
  17. Federal Office of Public Health. Number of hepatitis C cases reported in Switzerland between 1988 and 2012 by year of birth (mandatory notification of laboratory confirmed cases): FOPH/ID/EPI/RIC. 2013.
  18. Committee on a National Strategy for the Elimination of Hepatitis B, Board on Population H, Public Health P, Health, Medicine D, National Academies of Sciences E, et al. In: Buckley GJ, Strom BL, editors. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington (DC): National Academies Press; 2016.
  19. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593–4. doi:.https://doi.org/10.1001/jama.2014.8897
  20. Saag MS. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection. JAMA. 2014;312(4):347–8. doi:.https://doi.org/10.1001/jama.2014.7735
  21. Steinbrook R, Redberg RF. The high price of the new hepatitis C virus drugs. JAMA Intern Med. 2014;174(7):1172. doi:.https://doi.org/10.1001/jamainternmed.2014.2135
  22. Buti M, Domínguez-Hernández R, Oyagüez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat. 2017;24(9):750–8. doi:.https://doi.org/10.1111/jvh.12704
  23. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, et al.; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814–25. doi:.https://doi.org/10.1002/hep.29399
  24. Cacoub P, Buggisch P, Carrión JA, Cooke GS, Zignego AL, Beckerman R, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat. 2018;25(7):811–7. doi:.https://doi.org/10.1111/jvh.12881
  25. Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47(1):123–8. doi:.https://doi.org/10.1111/apt.14382
  26. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025–34. doi:.https://doi.org/10.1136/gutjnl-2018-316234
  27. Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67(3):553–61. doi:.https://doi.org/10.1136/gutjnl-2017-313983
  28. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228–37. doi:.https://doi.org/10.1001/jama.290.2.228
  29. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100(3):643–51. doi:.https://doi.org/10.1111/j.1572-0241.2005.40976.x
  30. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279–90. doi:.https://doi.org/10.7326/0003-4819-156-4-201202210-00005
  31. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20(12):847–57. doi:.https://doi.org/10.1111/jvh.12111

Most read articles by the same author(s)

1 2 3 > >>